Key result
Lower pretreatment TLG on PET/CT predicts ~72% lower mortality in metastatic ACC patients receiving chemotherapy.
Why the study?
[18F]FDG PET/CT is used for diagnosis and staging of adrenocortical cancer, but its prognostic role needed to be explored.
Do pretreatment [18F]FDG PET/CT parameters predict progression-free survival and overall survival in metastatic adrenocortical carcinoma patients treated with chemotherapy?
Cohort (n=41)
No
Do pretreatment [18F]FDG PET/CT parameters predict progression-free survival and overall survival in metastatic adrenocortical carcinoma patients treated with chemotherapy?
Pretreatment [18F]FDG PET/CT total lesion glycolysis (TLG) is an independent prognostic factor for progression-free and overall survival in metastatic adrenocortical carcinoma patients treated with chemotherapy.
Answers are grounded in this paper and cite their sources.
Supports TLG for risk stratification before EDP-M in metastatic ACC; extends independent prognostic value of pretreatment FDG-PET/CT.
[18F]-fluorodesoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) is used for diagnosis and staging of adrenocortical cancer (ACC), its prognostic role needs to be explored. This study aimed to investigate the prognostic role of pre-EDP-M [18F]FDG PET/CT parameters in ACC patients treated with first line chemotherapy (ChT) in term of progression free survival (PFS) and overall survival (OS). this retrospective, monocentric study included metastatic ACC patients treated with EDP-M after [18F]FDG PET/CT staging. Clinico-pathological features and PET/CT semiquantitative parameters such as standardized uptake value (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG), SUVmax/liver ratio (SL) and SUVmax/blood-pool ratio (SBP) were collected. forty-one ACC patients were included. Median PFS was 9.3 months and median OS was 14.3 months. PET/CT parameters did not correlate with the response to ChT, while they were affordable prognosticators. Lower MTV (HR 0.36, CI: 0.17–0.74; p < 0.01), lower TLG (HR 0.31, CI: 0.15–0.64; p < 0.01), lower tumour burden (HR 0.45, CI: 0.23–0.94; p = 0.03), attained the statistical significance in univariable analysis in terms of longer PFS, lower TLG (HR 0.33, CI: 0.15–0.71; p < 0.01) confirmed its independent role in multivariable analysis. At univariable analysis lower MTV (HR 0.36, CI: 0.16–0.82; p = 0.01) correlated with longer OS. Lower TLG confirmed its role in the multivariate analysis (HR 0.28, CI 0.11–0.69; p < 0.01). pretreatment TLG was reported as independent prognostic tools for ACC patients treated with EDP-M. No correlations between PET/CT parameters and response to ChT were reported.
No takes yet. Share an insight, caveat, or question.
Dondi et al. (2026) conducted a cohort in Metastatic adrenocortical carcinoma (ACC) (n=41). Lower pretreatment Total Lesion Glycolysis (TLG) on [18F]FDG PET/CT vs. Higher pretreatment TLG was evaluated on Overall survival (OS) (HR 0.28, 95% CI 0.11-0.69, p=<0.01). Lower pretreatment total lesion glycolysis on [18F]FDG PET/CT was independently associated with a lower risk of death in metastatic adrenocortical carcinoma patients.
Synapse has enriched 10 related papers. Consider them for comparative context: